KORU Medical Systems, Inc. (KRMD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlighted strong growth in prefilled syringes, a strategic focus on expanding international markets, and a positive cash flow reinvestment plan. Although there were some delays and uncertainties, the company is mitigating these effectively. The Q&A section revealed optimism about future growth, particularly with new product launches and international expansion. Overall, the sentiment is positive, with potential for stock price appreciation given the strong business fundamentals and strategic initiatives.
Key Financial Performance
Revenue Record revenues of $10.2 million in Q2 2025, representing 21% growth over the prior year period. Domestic core revenues were $7.1 million, a 15% increase over the prior year. International core business revenues were $2.2 million, representing growth of 34% over the prior year. Pharma Services and Clinical Trials revenues were $900,000, representing 42% growth over the prior year. Growth was driven by new patient starts, market share gains, expansion into new geographies, and clinical trial orders from a non-Ig partner.
Gross Margin Second quarter margins were 63.5%, representing a 150-basis point decline year-over-year. This decline was primarily driven by tariff impacts (90 basis points) and prior year favorable inventory revaluation adjustments (90 basis points). These were partially offset by volume efficiencies and improved Pharma Services and Clinical Trials margins.
Cash Usage Q2 cash usage was $600,000, driven by lower net losses resulting from higher revenues, sustained gross margins, and disciplined operating expense spending. Cash balance at the end of the quarter was $8.1 million. Cash usage for the first half of 2025 was $1.5 million, with expectations of neutral to positive cash usage in the second half of 2025.
Adjusted EBITDA Improved 101% to be slightly positive compared to a negative $1.3 million in the first half of 2024. This improvement was driven by higher revenues and disciplined capital allocation.
Adjusted Earnings Per Share $0.00 per share in the first half of 2025, compared to a loss of $0.02 per share in the same period last year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Freedom system: Serves approximately 45,000 patients primarily on Ig therapy for chronic conditions. Cleared for use with all SCIg drugs on the market. Submitted a 510(k) for a rare disease biologic ahead of schedule.
Next-gen pump: Development is on track with 510(k) submission expected by Q4 2025 to Q1 2026. Will accommodate all available prefilled syringes and offer improved mobility and usability.
Phase I flow controller: Launched ahead of schedule in Q2 2025. Phase II submission expected by the first half of 2026.
International expansion: Achieved over 30% growth in international markets. Expanded into new geographies and initiated prefilled syringe market conversion in Europe.
Oncology pilot program: Initiated a U.S.-based oncology pilot program with over 50 patients enrolled at 6 infusion centers across 4 subcutaneous oncology drugs.
Revenue growth: Achieved a historic milestone of over $10 million in revenue for Q2 2025, representing over 20% growth.
Profitability trajectory: Cash usage reduced to $600,000 in Q2 2025. On track for positive cash flow from operations for the full year 2025.
New drug pipeline: Pipeline includes 10 drugs, with 5 expected to be commercialized by the end of 2026. Revised total addressable market for new drugs is approximately $1.8 billion.
Empaveli expanded indication: FDA approved expanded indication for Empaveli, representing approximately 100,000 annual infusions, with KORU's opportunity estimated at 20,000 infusions.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Impacts: The company experienced a 90 basis point decline in gross margins due to tariff impacts, which is expected to continue affecting margins in the second half of the year.
Supply Chain Inflationary Pressures: Ongoing inflationary pressures in the supply chain are contributing to gross margin pressures, particularly in international markets with lower average selling prices.
Regulatory Approvals: The company is awaiting regulatory clearance for its flow controller with a third Ig drug in Japan, expected in 2026, which could delay market entry and revenue realization.
International Market Challenges: Expansion into international markets is associated with lower average selling prices, which could impact overall revenue growth and profitability.
Inventory Reduction: An expected inventory reduction from a large U.S. distributor in Q3 could negatively impact revenue in the short term.
R&D and Capital Expenditures: Higher operating expenses in the second half of 2025, driven by R&D project work and capital expenditures, could strain cash flow and profitability.
Regulatory Delays: Delays in filing and clearance of new products, such as the next-gen pump and consumable sets, could impact the timeline for revenue growth and market expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company raised its revenue guidance to $39.5 million to $40.5 million for 2025, representing 18% to 20% growth. This increase is driven by significant opportunities for further growth from prefilled conversions internationally, partially offset by an expected inventory reduction from a large distributor in the U.S. in Q3.
Gross Margin Guidance: Gross margins are expected to be in the range of 61% to 63% for the full year 2025. The second half of the year will see gross margin pressures due to a stronger mix of growth in international markets with lower average selling prices, supply chain inflationary pressures, and tariffs. Pricing and manufacturing efficiencies are expected to mitigate some of these impacts.
Cash Flow Guidance: The company expects to achieve positive cash flow from operations for the full year 2025, with cash usage for the second half expected to be neutral to positive. The year is projected to end with at least $8.1 million in cash.
Operating Expenses: Operating expenses, exclusive of stock compensation, are anticipated to be in the range of $26 million to $27 million for 2025, with higher spending in the second half driven by R&D project work.
Capital Expenditures: The company expects less than $2 million in investing activities and capital expenditures for new production lines in 2025.
Pipeline and Product Development: The company plans to file 510(k) submissions for three new drugs by Q1 2026. The next-generation pump development is on track, with a 510(k) submission expected by Q4 2025 to Q1 2026. The Phase II flow controller submission is expected by the first half of 2026, and a 510(k) for new consumable sets is planned for the second half of 2026.
International Expansion: The company is focusing on international expansion, particularly in prefilled syringe markets, with significant growth expected in the back half of 2025. Sales in Japan are anticipated in the second half of 2025, following the completion of pump and consumable registrations.
New Drug Pipeline: The pipeline includes five new drugs expected to be commercialized on the Freedom Infusion platform by the end of 2026, with 10 total pipeline drugs. Two drugs, deferoxamine and vancomycin, are expected to receive clearance by 2026, representing approximately $500,000 in incremental revenue next year. The FDA recently approved an expanded indication for Empaveli, representing approximately 20,000 annual infusions for KORU.
Long-Term Growth Vision: The company aims to sustain 20%+ growth through investments in core, international, and new product and drug pipeline initiatives. The revised total addressable market for new drugs is approximately $1.8 billion.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you parse out expectations for domestic versus OUS (Outside the US) performance and the cadence in Q3 versus Q4?
A:The international segment is driving tremendous growth and is expected to accelerate in the back half of the year. Domestically, there is a temporary drop-off in Q3 due to a U.S. distributor's inventory reduction program, but a bounce-back is expected in Q4. The PST (clinical trials and services) business is expected to show stable growth similar to the first half of the year.
Q:What is driving the success of prefilled syringes in Europe, and how durable is this growth opportunity?
A:The success is driven by the conversion of drugs from vials to prefilled syringes, which reduces steps by over 40% and has a 75% patient preference. The company’s Freedom system is well-suited for this transition. The market share in Europe has increased from 10-15% to the low 20s, and further conversions are expected in the back half of the year and into 2026. The company is working with pharma partners to expand into new markets.
Q:What is the market share in the converted international market compared to Europe overall?
A:The overall market share in Europe is in the low 20s, up from 10-15%. Specific market share data for the converted market is not yet available, but the company believes it was lower than average due to competition. More details will be gathered in the coming months.
Q:What is the growth rate of the domestic SCIg market, and what are the expectations for the remainder of the year?
A:The domestic SCIg market has been growing at high single-digit to low double-digit rates. Pharma partners are reporting strong double-digit growth in their SCIg franchises, driven by new patient starts and diagnoses. A trial for secondary immunodeficiency, a strong driver in Europe, is expected to further boost growth in the U.S. once concluded.
Q:What caused the consumable delay, and what is the status of the next-gen pump?
A:The consumable delay was due to improvements in comfort (needle technology) and convenience (reducing steps for infusion). Adjustments are being made based on customer feedback, but this will not impact 2025 or 2026 revenues. The next-gen pump has cleared major technical hurdles and is expected to be submitted for U.S. 510(k) approval by the end of Q1 2026, with EU submission following a quarter later.
Q:Why is the next-gen pump important, particularly for OUS, and what is the timeline for its clearance and launch?
A:The next-gen pump simplifies the use of multiple prefilled syringes of varying sizes, offering expanded mobility, dosing windows, and ease of use. It is expected to be submitted for U.S. 510(k) approval by the end of Q1 2026, with EU submission by mid-2026.
Q:What is the impact of tariffs, and how is the company mitigating them?
A:Tariffs have about a 90-basis-point impact, roughly 2% on every order. The company is mitigating this through operational excellence programs, creating efficiencies, and leveraging volume-based rebates from vendors. They feel confident in managing the tariff-related impact.
Q:Is the distributor impact in the U.S. expected to be limited to Q3?
A:Yes, the distributor impact is expected to be a one-time event in Q3 due to a company goal to reduce a week of inventory. End-user demand remains strong, and the impact is not expected to affect other growth drivers.
Q:How is the company planning to use its positive cash flow, and what are the priorities for reinvestment?
A:The company plans to maintain an $8 million cash balance and reinvest in growth opportunities with a focus on SG&A. Investments will target international opportunities and new markets, with a preference for projects with a one-year payback. Larger opportunities, such as oncology, may require additional funding.
Q:What is the expected commercial uptake of the new pipeline with new drugs and expanded indications?
A:The company expects linear progression in uptake, with approximately $1 million in upside from vancomycin, deferoxamine, Empaveli, and a rare disease indication in 2024. Larger opportunities, such as oncology, could provide significant growth but require further work on reimbursement and economics.
Q:What is the outlook for international growth, including the impact of the Japan launch?
A:International growth is expected to accelerate significantly in the back half of the year, with the Japan launch contributing more in 2026 than 2025. The $1 million guidance increase is primarily attributed to international growth, which is expected to be evenly distributed across Q3 and Q4.
Q:What is the status of the tender win from Q1, and what is its expected impact?
A:The tender win from Q1 is included in the guidance, with equally strong orders expected in the back half of the year.
Q:What drove the increase in Pharma Services and Clinical Trials revenue, and is this sustainable?
A:The increase was driven by clinical trial orders for a non-Ig drug in Phase III. While encouraging, this quarter’s revenue is not expected to be the new norm. PST revenues for the front and back halves of the year are expected to be similar, with potential upside from new opportunities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific market share data for the converted international market, stating that they do not yet have the details and will gather more information in the coming months.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
FDA indication
Freedom system
Group LLC
IV
Ig drug
Ig therapy
Infusion platform
KORU opportunity
LLC Research
PST
Research Division
acceleration
capital allocation
controller
core Ig
decision
decline
delivery drug
delivery market
disease biologic
drug Freedom
drug patient
expansion geography
formulation
generation
highlight
impact
increase ability
indication Empaveli
label expansion
partnership
pillar
pilot
pump development
schedule disease
strength
success
tariff
trajectory
volume drug
KRMD Transcript
KORU Medical Systems, Inc. (KRMD) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong financial performance with a 15% revenue increase and a 40% rise in net income, alongside improved gross margins. These indicators, coupled with positive cash flow, suggest robust financial health. Despite the absence of strategic updates, the financial metrics and optimistic forward-looking statements indicate potential for positive stock movement. The lack of negative sentiment in the Q&A further supports a positive outlook, likely resulting in a 2% to 8% stock price increase over the next two weeks.
KORU Medical Systems, Inc. (KRMD) Q4 2025 Earnings Call Transcript
Positive3-12
The earnings call reveals strong financial performance with a 23% YoY revenue growth and international expansion. The company raised its revenue guidance, maintained positive cash flow, and achieved positive adjusted EBITDA. Despite slight margin decreases, the strategic focus on expanding market share and new product launches is promising. The Q&A highlights further growth potential in international markets and new drug approvals. The overall sentiment is positive, with expectations of continued growth driven by strategic initiatives and market expansion, suggesting a likely positive stock price movement.
KORU Medical Systems, Inc. (KRMD) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call indicates strong international revenue growth and positive cash flow. Despite domestic revenue decline, the company has raised its revenue guidance and aims for 20%+ growth. The Q&A section highlights high nurse satisfaction and workflow improvements, existing reimbursement codes, and strong international expansion plans. Gross margin pressures are acknowledged but are being addressed. Overall, the optimistic guidance, international expansion, and raised revenue forecast outweigh domestic challenges, suggesting a positive stock price movement.
KORU Medical Systems, Inc. (KRMD) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call highlighted strong growth in prefilled syringes, a strategic focus on expanding international markets, and a positive cash flow reinvestment plan. Although there were some delays and uncertainties, the company is mitigating these effectively. The Q&A section revealed optimism about future growth, particularly with new product launches and international expansion. Overall, the sentiment is positive, with potential for stock price appreciation given the strong business fundamentals and strategic initiatives.
KRMD Slides
KRMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
